Researcher profile

Yusi Fang

Yusi Fang contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 13 - UnverifiedVerification L1Unclaimed author
2works
0followers
2topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2022arXiv

On p-value combination of independent and frequent signals: asymptotic efficiency and Fisher ensemble

Combining p-values to integrate multiple effects is of long-standing interest in social science and biomedical research. In this paper, we focus on revisiting a classical scenario closely related to meta-analysis, which combines a relatively small (finite and fixed) number of p-values while the sample size for generating each p-value is large (asymptotically goes to infinity). We evaluate a list of traditional and recently developed modified Fisher's methods to investigate their asymptotic efficiencies and finite-sample numerical performance. The result concludes Fisher and adaptively weighted Fisher method to have top performance and complementary advantages across different proportions of true signals. Finally, we propose an ensemble method, namely Fisher ensemble, to combine the two top-performing Fisher-related methods using a robust truncated Cauchy ensemble approach. We show that Fisher ensemble achieves asymptotic Bahadur optimality and integrates the strengths of Fisher and adaptively weighted Fisher methods in simulations. We subsequently extend Fisher ensemble to a variant with emphasized power for concordant effect size directions. A transcriptomic meta-analysis application confirms the theoretical and simulation conclusions, generates intriguing biomarker and pathway findings and demonstrates strengths and strategy of using proposed Fisher ensemble methods.

preprint2020arXiv

Outcome-Guided Disease Subtyping for High-Dimensional Omics Data

High-throughput microarray and sequencing technology have been used to identify disease subtypes that could not be observed otherwise by using clinical variables alone. The classical unsupervised clustering strategy concerns primarily the identification of subpopulations that have similar patterns in gene features. However, as the features corresponding to irrelevant confounders (e.g. gender or age) may dominate the clustering process, the resulting clusters may or may not capture clinically meaningful disease subtypes. This gives rise to a fundamental problem: can we find a subtyping procedure guided by a pre-specified disease outcome? Existing methods, such as supervised clustering, apply a two-stage approach and depend on an arbitrary number of selected features associated with outcome. In this paper, we propose a unified latent generative model to perform outcome-guided disease subtyping constructed from omics data, which improves the resulting subtypes concerning the disease of interest. Feature selection is embedded in a regularization regression. A modified EM algorithm is applied for numerical computation and parameter estimation. The proposed method performs feature selection, latent subtype characterization and outcome prediction simultaneously. To account for possible outliers or violation of mixture Gaussian assumption, we incorporate robust estimation using adaptive Huber or median-truncated loss function. Extensive simulations and an application to complex lung diseases with transcriptomic and clinical data demonstrate the ability of the proposed method to identify clinically relevant disease subtypes and signature genes suitable to explore toward precision medicine.